{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:12:47Z","timestamp":1793041967384,"version":"4.5.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002920","name":"Research Grants Council, University Grants Committee","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001839","name":"University Grants Committee","doi-asserted-by":"publisher","award":["12102120"],"award-info":[{"award-number":["12102120"]}],"id":[{"id":"10.13039\/501100001839","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001839","name":"University Grants Committee","doi-asserted-by":"publisher","award":["12102322"],"award-info":[{"award-number":["12102322"]}],"id":[{"id":"10.13039\/501100001839","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001839","name":"University Grants Committee","doi-asserted-by":"publisher","award":["T12-201\/20-R"],"award-info":[{"award-number":["T12-201\/20-R"]}],"id":[{"id":"10.13039\/501100001839","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.omton.2025.201044","type":"journal-article","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T15:02:31Z","timestamp":1756566151000},"page":"201044","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Targeting BCMA in multiple myeloma: A comprehensive review of immunotherapeutic strategies and clinical outcomes"],"prefix":"10.1016","volume":"33","author":[{"given":"Chi Ho","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minchuan","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1276-5695","authenticated-orcid":false,"given":"Yuanyuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2025.201044_bib1","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.3892\/ol.2016.5095","article-title":"BCMA and TACI proteins are abnormally expressed in non-small cell lung cancer","volume":"12","author":"Dou","year":"2016","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.omton.2025.201044_bib2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.omton.2025.201044_bib3","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.omton.2025.201044_bib4","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","article-title":"BCMA-targeted immunotherapy for multiple myeloma","volume":"13","author":"Yu","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.omton.2025.201044_bib5","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","article-title":"Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy","volume":"9","author":"Cho","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2025.201044_bib6","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13045-022-01296-2","article-title":"Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?","volume":"15","author":"Kegyes","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.omton.2025.201044_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15082240","article-title":"Targeting BCMA in Multiple Myeloma: Advances in Antibody-Drug Conjugate Therapy","volume":"15","author":"Xing","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omton.2025.201044_bib8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3892\/ijo.2016.3516","article-title":"Multiple myeloma and persistence of drug resistance in the age of novel drugs (Review)","volume":"49","author":"Krishnan","year":"2016","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.omton.2025.201044_bib9","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1182\/blood-2003-06-2043","article-title":"Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival","volume":"103","author":"Novak","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.201044_bib10","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.omton.2025.201044_bib11","doi-asserted-by":"crossref","first-page":"D439","DOI":"10.1093\/nar\/gkab1061","article-title":"AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models","volume":"50","author":"Varadi","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omton.2025.201044_bib12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nature01543","article-title":"Ligand\u2013receptor binding revealed by the TNF family member TALL-1","volume":"423","author":"Liu","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.omton.2025.201044_bib13","doi-asserted-by":"crossref","first-page":"7218","DOI":"10.1074\/jbc.M411714200","article-title":"Structures of APRIL-receptor complexes: like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding","volume":"280","author":"Hymowitz","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omton.2025.201044_bib14","doi-asserted-by":"crossref","first-page":"16727","DOI":"10.1074\/jbc.M312316200","article-title":"Engineering an APRIL-specific B cell maturation antigen","volume":"279","author":"Patel","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omton.2025.201044_bib15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.smim.2006.04.006","article-title":"BAFF, APRIL and their receptors: Structure, function and signaling","volume":"18","author":"Bossen","year":"2006","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.omton.2025.201044_bib16","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.4049\/jimmunol.165.3.1322","article-title":"TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF) 1, TRAF2, and TRAF3 and activates NF-kappa B, elk-1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase","volume":"165","author":"Hatzoglou","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.omton.2025.201044_bib17","doi-asserted-by":"crossref","first-page":"9156","DOI":"10.1073\/pnas.160213497","article-title":"B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1","volume":"97","author":"Shu","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2025.201044_bib18","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1038\/ncomms8333","article-title":"\u03b3-Secretase directly sheds the survival receptor BCMA from plasma cells","volume":"6","author":"Laurent","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2025.201044_bib19","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.leukres.2019.04.008","article-title":"Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells","volume":"81","author":"Chen","year":"2019","journal-title":"Leuk. Res."},{"key":"10.1016\/j.omton.2025.201044_bib20","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1182\/blood.2019000050","article-title":"\u03b3-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma","volume":"134","author":"Pont","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.201044_bib21","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3324\/haematol.2016.150896","article-title":"Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients","volume":"102","author":"Ghermezi","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.omton.2025.201044_bib22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.coi.2021.06.015","article-title":"Endogenous soluble receptors sBCMA and sTACI: biomarker, immunoregulator and hurdle for therapy in multiple myeloma","volume":"71","author":"Meinl","year":"2021","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.omton.2025.201044_bib23","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.3390\/cimb44040098","article-title":"sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma","volume":"44","author":"Seipel","year":"2022","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.omton.2025.201044_bib24","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1182\/blood-2019-126115","article-title":"Targeting B-Cell Maturation Antigen (BCMA) with CC-93269, a 2+1 T Cell Engager, Elicits Significant Apoptosis in Diffuse Large B-Cell Lymphoma Preclinical Models","volume":"134","author":"Hagner","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.201044_bib25","first-page":"2755","article-title":"B- Cell Maturation Antigen Is Exclusively Expressed in a Wide Range of B-Cell and Plasma Cell Neoplasm and in a Potential Therapeutic Target for Bcma Directed Therapies","volume":"130","author":"Khattar","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.201044_bib26","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.3389\/fimmu.2020.01985","article-title":"Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes","volume":"11","author":"Schultz","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2025.201044_bib29","unstructured":"Celgene Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release. https:\/\/ClinicalTrials.gov\/show\/NCT04771078."},{"key":"10.1016\/j.omton.2025.201044_bib30","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.omton.2025.201044_bib31","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up","volume":"41","author":"Martin","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2025.201044_bib32","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1200\/JCO-25-00760","article-title":"Long-Term (\u22655-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed\/Refractory Multiple Myeloma","volume":"43","author":"Jagannath","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.omton.2025.201044_bib33","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1182\/blood-2020-140641","article-title":"Universal: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed\/Refractory Multiple Myeloma","volume":"136","author":"Mailankody","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.201044_bib34","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omton.2025.201044_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9072166","article-title":"Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma","volume":"9","author":"Zhou","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.omton.2025.201044_bib36","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.drudis.2015.02.008","article-title":"Bispecific antibodies","volume":"20","author":"Kontermann","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.omton.2025.201044_bib37","series-title":"Translational Biotechnology","first-page":"233","article-title":"Chapter 9 - Bispecific antibodies: A promising entrant in cancer immunotherapy","author":"Saini","year":"2021"},{"key":"10.1016\/j.omton.2025.201044_bib38","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1158\/2643-3230.BCD-21-0028","article-title":"Bispecific Antibodies in Multiple Myeloma: Present and Future","volume":"2","author":"Lancman","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.omton.2025.201044_bib39","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1038\/leu.2016.388","article-title":"A novel BCMA\/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo","volume":"31","author":"Hipp","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2025.201044_bib40","first-page":"5389","article-title":"Generation of Half-Life Extended Anti-BCMA Bite\u00ae Antibody Construct Compatible with Once-Weekly Dosing for Treatment of Multiple Myeloma (MM)","volume":"130","author":"Goyos","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.201044_bib41","doi-asserted-by":"crossref","DOI":"10.1177\/2040620721989585","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies","volume":"12","author":"Sanchez","year":"2021","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.omton.2025.201044_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2019.09.082","article-title":"AMG 701, a half-life extended anti-BCMA BiTE\u00ae, potently induces T cell-redirected lysis of human multiple myeloma cells and can be combined with IMiDs to overcome the immunosuppressive bone marrow microenvironment","volume":"19","author":"Cho","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.omton.2025.201044_bib43","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/blood-2019-122895","article-title":"First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed\/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial","volume":"134","author":"Costa","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.201044_bib44","first-page":"3082","article-title":"AFM26 - Targeting B Cell Maturation Antigen (BCMA) for NK Cell-Mediated Immunotherapy of Multiple Myeloma","volume":"130","author":"Gantke","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.201044_bib45","doi-asserted-by":"crossref","first-page":"8045","DOI":"10.1200\/JCO.2017.35.15_suppl.8045","article-title":"AFM26 is a novel, highly potent BCMA\/CD16A-directed bispecific antibody for high affinity NK-cell engagement in multiple myeloma","volume":"35","author":"Gantke","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2025.201044_bib46","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1182\/blood-2018-99-118970","article-title":"Preclinical Characterization of AFM26, a Novel B Cell Maturation Antigen (BCMA)-Directed Tetravalent Bispecific Antibody for High Affinity Retargeting of NK Cells Against Myeloma","volume":"132","author":"Ross","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.201044_bib47","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","article-title":"Antibody-Drug Conjugates: A Comprehensive Review","volume":"18","author":"Khongorzul","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.omton.2025.201044_bib48","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1007\/s11095-015-1624-3","article-title":"Evolving Strategies for Target Selection for Antibody-Drug Conjugates","volume":"32","author":"Damelin","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.omton.2025.201044_bib49","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.201044_bib50","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1182\/blood.V128.22.1148.1148","volume":"128","author":"Cohen","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.201044_bib51","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1182\/blood.V130.Suppl_1.741.741","article-title":"Deep and Durable Responses in Patients (Pts) with Relapsed\/Refractory Multiple Myeloma (MM) Treated with Monotherapy GSK2857916, an Antibody Drug Conjugate Against B-Cell Maturation Antigen (BCMA): Preliminary Results from Part 2 of Study BMA117159","volume":"130","author":"Trudel","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.201044_bib52","series-title":"Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916","article-title":"Dose Escalation Study to Investigate the Safety","year":"2014"},{"key":"10.1016\/j.omton.2025.201044_bib53","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omton.2025.201044_bib54","author":"GlaxoSmithKline"},{"key":"10.1016\/j.omton.2025.201044_bib55","unstructured":"GlaxoSmithKline, Sharp, M., and LLC, D. (2019). Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed\/Refractory Multiple Myeloma (RRMM).; https:\/\/www.clinicaltrials.gov\/study\/NCT03848845"},{"key":"10.1016\/j.omton.2025.201044_bib56","article-title":"Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma","author":"University of Pennsylvania","year":"2021","journal-title":"and GlaxoSmithKline"},{"key":"10.1016\/j.omton.2025.201044_bib57","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2403407","article-title":"Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma","volume":"391","author":"Dimopoulos","year":"2024","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.omton.2025.201044_bib58","author":"Institute"},{"key":"10.1016\/j.omton.2025.201044_bib59","series-title":"A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function","author":"GlaxoSmithKline","year":"2020"},{"key":"10.1016\/j.omton.2025.201044_bib60","series-title":"A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed\/Refractory Multiple Myeloma","author":"GlaxoSmithKline","year":"2019"},{"key":"10.1016\/j.omton.2025.201044_bib61","unstructured":"GlaxoSmithKline (2019). Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed\/Refractory Multiple Myeloma (RRMM) (DREAMM 5).; https:\/\/clinicaltrials.gov\/study\/NCT04126200"},{"key":"10.1016\/j.omton.2025.201044_bib62","doi-asserted-by":"crossref","first-page":"e14527","DOI":"10.1200\/JCO.2018.36.15_suppl.e14527","article-title":"HDP-101: Preclinical evaluation of a novel anti-BCMA antibody drug conjugates in multiple myeloma","volume":"36","author":"Pahl","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2025.201044_bib63","first-page":"3070","article-title":"Preclinical Evaluation of Hdp-101, a Novel Anti-BCMA Antibody-Drug Conjugate, in Multiple Myeloma","volume":"130","author":"Ko","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.201044_bib64","author":"AG"},{"key":"10.1016\/j.omton.2025.201044_bib65","first-page":"3153","article-title":"Preclinical Evaluation of MEDI2228, a BCMA-Targeting Pyrrolobenzodiazepine-Linked Antibody Drug Conjugate for the Treatment of Multiple Myeloma","volume":"130","author":"Kinneer","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.201044_bib66","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1182\/blood-2019-127135","article-title":"MEDI2228, a Novel Bcma Antibody-PBD Conjugate, Sensitizes Human Multiple Myeloma Cells to NK Cell-Mediated Cytotoxicity and Upregulates CD38 Expression in MM Cells","volume":"134","author":"Xing","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.201044_bib67","series-title":"MEDI2228 in Subjects With Relapsed\/Refractory Multiple Myeloma","author":"LLC","year":"2018"},{"key":"10.1016\/j.omton.2025.201044_bib68","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2020-136375","article-title":"Phase 1, First-in-Human Study of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed\/Refractory Multiple Myeloma","volume":"136","author":"Kumar","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.201044_bib69","article-title":"Emerging immunotherapies in multiple myeloma","volume":"370","author":"Shah","year":"2020","journal-title":"Bmj"},{"key":"10.1016\/j.omton.2025.201044_bib70","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2023-174841","article-title":"Updated Results of a Phase I Open-Label Single-Arm Study of Dual Targeting BCMA and CD19 Fastcar-T Cells (GC012F) As First-Line Therapy for Transplant-Eligible Newly Diagnosed High-Risk Multiple Myeloma","volume":"142","author":"Du","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.201044_bib71","doi-asserted-by":"crossref","first-page":"8014","DOI":"10.1200\/JCO.2021.39.15_suppl.8014","article-title":"Long-term follow-up results of a multicenter first-in-human study of the dual BCMA\/CD19 Targeted FasT CAR-T GC012F for patients with relapsed\/refractory multiple myeloma","volume":"39","author":"Jiang","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2025.201044_bib72","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2025.201044_bib73","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/j.ymthe.2022.04.002","article-title":"Gene therapy access: Global challenges, opportunities, and views from Brazil, South Africa, and India","volume":"30","author":"Cornetta","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2025.201044_bib74","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.201044_bib75","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1182\/bloodadvances.2024013640","article-title":"Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas","volume":"9","author":"Chong","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2025.201044_bib76","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1158\/1535-7163.MCT-19-0993","article-title":"Patient Selection Strategies to Maximize Therapeutic Index of Antibody\u2013Drug Conjugates: Prior Approaches and Future Directions","volume":"19","author":"Williams","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.omton.2025.201044_bib77","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2025.201044_bib78","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1182\/blood-2021-145572","article-title":"Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed\/Refractory Multiple Myeloma","volume":"138","author":"Mailankody","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.201044_bib79","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1182\/blood-2019-130340","article-title":"A Bispecific CAR-T Cell Therapy Targeting Bcma and CD38 for Relapsed\/Refractory Multiple Myeloma: Updated Results from a Phase 1 Dose-Climbing Trial","volume":"134","author":"Li","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.201044_bib80","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S1470-2045(23)00246-2","article-title":"\u03b3-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial","volume":"24","author":"Cowan","year":"2023","journal-title":"Lancet Oncol."}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329925001134?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329925001134?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T01:19:40Z","timestamp":1772155180000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329925001134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":78,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2950329925001134"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2025.201044","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting BCMA in multiple myeloma: A comprehensive review of immunotherapeutic strategies and clinical outcomes","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2025.201044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201044"}}